Drugs / MVF-HER2 266-296
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06949410 | Jun 2026 → Dec 2029 expected | HER2 positive breast carcinoma | Pravin T.P Kaumaya | Recruiting | No outcome recorded |
| Phase 1 | NCT06414733 | Jan 2025 → Dec 2029 expected | HER2 positive breast carcinoma, digestive system carcinoma | Pravin T.P Kaumaya | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVF-HER2 266-296 | “MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines” NCT06949410 ↗ |
| Action | Deplete | “Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.” NCT06414733 ↗ |
| Modality | Peptide | “HER-2 B Cell Peptide Vaccine” NCT06414733 ↗ |
| Route | Intramuscular | “Three intramuscular (IM) injections (separated by 21 days)” NCT06414733 ↗ |